CHECK TREATMENT ELIGIBILITY

Enter your patient's mutations below

TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data. 

Mutation 1
Mutation 2 (optional)
Eligible

Mutation(s) not recognized. Please check to see if they were entered correctly.

Results

Learn how to enter 2 or more mutations

>18,900 PATIENTS AGED 6 YEARS AND OLDER HAVE INITIATED treatment with TRIKAFTA

>90% OF ALL PATIENTS HAVE REMAINED on TRIKAFTA

aData from prescriptions received by specialty pharmacies through March 11, 2022. Data does not include patients’ CF gene mutations and does not reflect patients who have stopped treatment.